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Methods: Subjects not currently receiving acetylcholinesterase inhibitors were randomized to ABT-
126 (5 or 25 mg once daily), donepezil 10 mg once daily, or placebo for 12 weeks. The primary ef-
ficacy end point was the change from baseline to final evaluation in the 11-item Alzheimer’s Disease
Assessment Scale-cognitive subscale (ADAS-Cog) total score.
Results: Atotal of 274 subjectswere randomized.Although the study didnotmeet its primary end point,
trends toward improvement were seen with ABT-126 25 mg (least squares mean [standard error] differ-
ence from placebo21.19 [0.90]; one-sided P5 .095) and donepezil (21.43 [0.90]; one-sided P5 .057)
on the 11-item ADAS-Cog total score change from baseline to the final evaluation. ABT-126 5 mg was
numerically similar to placebo. An exposure-response analysis indicated a statistically significant rela-
tionship betweenABT-126 exposure and the change from baseline in ADAS-Cog, with no evidence of a
plateau. No clinically meaningful differences in safety were observed among treatment groups.
Discussion: Although the ABT-126 25mg dose did not demonstrate statistically significant improve-
ment, results of the exposure-response analysis suggest that higher doses may produce better efficacy,
and the safety profile of ABT-126 in this study supports additional studies with higher doses in sub-
jects with mild-to-moderate AD.
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tic plasticity associated with learning and memory [1]. a-7
nAChRs modulate the release of multiple neurotransmit-
ters such as dopamine, glutamate, and acetylcholine [2]
and activate intracellular signaling cascades such as
cyclic-adenosine monophosphate response element bind-
ing and extracellular signal-regulated kinases. The mecha-
nism of action for the a7 nAChR agonists is distinct from
that of acetylcholinesterase inhibitors (AChEIs) that
inhibit the enzymatic breakdown of acetylcholine, sug-
gesting that they will provide a different efficacy and
safety profile [3].imer’s Association. This is an open access article under the CC BY-NC-ND
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improve cognition in Alzheimer’s dementia (AD). Positive
effects with a7 nAChR agonists and partial agonists have
been observed in preclinical models of cognition [4–8].
Procognitive effects have also been reported with the
partial a7 agonist EVP-6124 (encenicline) as a stand-alone
treatment for AD or as an add-on treatment to AChEIs [9].
An initial study with another a7-nAChR partial agonist
MEM3454/RG3487 also showed procognitive effects in
subjects with AD [10] but the results were not replicated
in a subsequent larger phase 2 add-on study [11].
ABT-126 is a potent and selective a7 nAChR agonist
demonstrating efficacy in animal models across multiple
cognitive domains relevant to AD, including social recogni-
tion memory, memory consolidation, inhibitory avoidance,
and working memory [12]. Data from phase 1 studies of
healthy adults, elderly subjects, and subjects with schizo-
phrenia indicated that ABT-126 was generally well toler-
ated. This phase 2 proof-of-concept study was designed to
evaluate the efficacy and safety of two doses of ABT-126
compared with placebo and donepezil for the symptomatic
treatment of mild-to-moderate AD.2. Methods
2.1. Study subject recruitment
This phase 2, double-blind, parallel, randomized, pla-
cebo- and active-controlled study was conducted at 27 sites
in the United States, Bulgaria, Czech Republic, Slovakia,
United Kingdom, and South Africa.
Eligible male and female subjects were aged 55–90 years,
met National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association criteria for probable AD
[13], had reliable caregivers, a Mini-Mental Status Examina-
tion (MMSE) [14] score from 10 to 24, a Cornell Scale for
Depression in Dementia (CSDD) [15] score 10, and a
Modified Hachinski Ischemic Scale [16] score of 4 at the
initial screening visit. Subjects were in general good health
with no evidence of an alternative etiology for dementia on a
computed tomography or magnetic resonance imaging per-
formed within the previous 36 months. Subjects were
excluded if they were currently taking or had taken an AD
medication within 60 days before the first screening visit
or if they were receiving cognitive therapy for AD. Concom-
itant pharmacologic treatments for AD were prohibited
during the study. Vitamins and herbal supplements (with
the exception of huperzine), antidepressants, low-dose anxi-
olytics, hypnotics, atypical antipsychotics, and pain and uri-
nary incontinence medications were allowed provided
treatment started.30 days before screening and were antic-
ipated to remain stable. Subjects who had stopped donepezil
therapy due to intolerance or a lack of efficacy after an
adequate trial were also excluded.2.2. Standard protocol approvals, registrations, and
patients consents
The protocol, amendments, and informed consent forms
were approved by an independent ethics committee or insti-
tutional review board. Written informed consent was ob-
tained from each participant (or their representative) and
their caregivers before screening procedures.
2.3. Study design
The study began with a screening period of up to 28 days
that included two screening visits and a baseline visit
(day 21). Subjects were randomized 1:1:1:1 to 12 weeks of
treatment with placebo, ABT-126 5 mg, ABT-126 25 mg, or
donepezil 10 mg once daily. Donepezil was initiated at 5 mg
once daily for 4 weeks followed by 10 mg for 8 weeks.
ABT-126 5 and 25 mg were expected to result in plasma con-
centrationswithin and above the predicted efficacy range from
preclinical studies, respectively, for 24 hours. Study drug was
identical in appearance to preserve the blind. Randomization
occurred via an interactive voice response and interactive
Web-based system using a randomization code provided by
the sponsor, stratified by study site. Visits were at weeks 2,
4, 8, 12/early discontinuation, and follow-up (approximately
2 weeks after the last dose). Safety telephone assessments
occurred at weeks 6 and 10 and 30 days after the last dose.
An independent safety data monitoring committee re-
viewed unblinded safety data during the study and made rec-
ommendations regarding trial conduct according to a
predefined charter. Six interim efficacy evaluations were
conducted according to a prespecified algorithm by an un-
blinded external statistician and an unblinded sponsor statis-
tician not involved in other aspects of the study. These
analyses provided a mechanism to cease enrollment to an
inefficacious dose of ABT-126 or to terminate the entire
study early due to futility of both ABT-126 dose groups.
Evaluations were conducted when approximately 100, 120,
140, 160, 180, and 200 subjects had completed or discontin-
ued from the study. If a dose demonstrated a predictive prob-
ability of .10 that the final P value of the ABT-126 dose
versus placebo would be .05 for three consecutive interim
evaluations or the predictive probabilities showed a
decreasing trend for three consecutive evaluations with the
last evaluation reaching the threshold of .10, then no addi-
tional subjects would have been enrolled in that dose group.
The sites were not informed of the timing of the conduct or
the outcome of these evaluations.
2.4. Assessments
The primary efficacy measure was the 11-item Alz-
heimer’s Disease Assessment Scale-cognitive subscale
(ADAS-Cog). Secondary efficacy measures included total
scores of the 13-item ADAS-Cog [17,18], the MMSE, the
Clinician Interview-Based Impression of Severity (CIBIS,
baseline only), the Clinician Interview-Based Impression
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ventory (10- and 12-item) [20,21], and the Alzheimer’s
Disease Cooperative Study Activities of Daily Living
(ADSC-ADL) [22] scale and the subject and caregiver scores
of the Quality of Life - Alzheimer’s Disease [23] scale.
Safety was assessed via adverse events (AEs), vital signs,
electrocardiograms (ECGs), physical examinations, brief
neurologic examinations, brief psychiatric assessments,
clinical laboratory assessments, the CSDD, and the Physi-
cian Withdrawal Checklist (PWC-20) [24]. One blood sam-
ple for pharmacokinetic analysis was collected at weeks 2, 4,
8, and 12.2.5. Statistical methods
With approximately 65 subjects per treatment group (260
total) and assumed pooled standard deviation (SD) of six, the
study was designed to have 80% power to detect a treatment
difference of 23.08 change from baseline to final observa-
tion on the 11-item ADAS-Cog total score between an
ABT-126 dose group and placebo at a one-sided significance
level of .05 (assumed pooled SD of six based on AChEIs’ ef-
fect in studies of 12–24 weeks duration) [25]. The study was
powered to detect an effect size of approximately 0.5, which
is approximately 30% greater than the average effect size of
AChEIs because newer medications for AD need to demon-
strate larger effects than AChEIs to provide a useful alterna-
tive therapy to patients. Because of the exploratory nature of
the study, a one-sided test was used for all efficacy analyses
to quantify statistical significance when an ABT-126 dose
group demonstrated greater numerical improvement
compared with placebo. Therefore, all reported P values
for efficacy variables are one-sided. There was no adjust-
ment for multiple comparisons of two ABT-126 treatment
groups. With the exception of the 13-item ADAS-Cog
outcome, this proof-of-concept study was not powered to
detect significant differences on any other efficacy variables,
which generally have smaller effect sizes compared with the
ADAS-Cog 11-item total score. For the interim analyses, fu-
tility criteria were based on Bayesian predictive probability
as described previously. There was no hypothesis testing at
the interim analyses, and the significance level for statistical
testing at the final analysis remained at .05.
Efficacy and safety populations included all subjects who
tookone dose of study drug. The primary efficacy variable
was the change from baseline to the final evaluation in the
11-item ADAS-Cog total score. The primary efficacy anal-
ysis was conducted using an analysis of covariance (AN-
COVA) model with treatment and study site as the main
effects and baseline score as the covariate. The difference
between an ABT-126 dose group and placebo and the differ-
ence between donepezil and placebo were tested at a one-
sided significance level of .05. Type III sum-of-squares
was used to generate the least squares (LS) means of
treatment-group differences. As a sensitivity analysis,
treatment-group differences for the change from baselineto weeks 4, 8, and 12 on the 11-item ADAS-Cog total score
were assessed using a mixed-effects, maximum likelihood,
repeated measures (MMRM) analysis. The model included
fixed effects of treatment, study site, visit, and treatment-
by-visit interaction, with baseline score as a covariate, and
the baseline-by-visit interaction.
All secondary efficacy variables except the CIBIC-plus
were analyzed by the ANCOVA model as described for the
primary efficacy analysis to evaluate treatment group differ-
ences in change from baseline to final. The change from
baseline to each postbaseline assessment in the 13-item
ADAS-Cog, MMSE, NPI (10- and 12-item), and ADSC-
ADL total scores were also analyzed using the aforemen-
tioned MMRM analysis model.
The final observation of the CIBIC-plus was analyzed by
an ANCOVA model with the terms of treatment and study
site with CIBIS score collected at baseline as a covariate.
Longitudinal assessments of CIBIC-plus scores were
analyzed by an MMRM analysis with the fixed effects of
treatment, study site, visit, treatment-by-visit interaction,
with the baseline CIBIS score as continuous covariate. The
percentage of subjects with any improvement in the final
CIBIC-plus assessment was compared between placebo
and each ABT-126 dose group using Fisher’s exact test.
Prespecified subgroup analyses were performed on the
11-item ADAS-Cog using an ANCOVA model with the
terms of treatment, study site, and subgroup variable, and
the treatment-by-subgroup variable interaction to determine
any effect of baseline MMSE (19 or 20), gender, age
(,65 or 65), country, and APOE ε4 allele status (ε41 or
ε42). The baseline 11-item ADAS-Cog total score was
included as a covariate. A treatment-by-subgroup interaction
P value .10 was considered significant.
Comparisons between each ABT-126 dose group and pla-
cebo for safety parameters were performed with two-sided
tests at the significance level of .05. AEs were coded using
the Medical Dictionary for Regulatory Activities [26].2.6. Exposure-response analysis
Nonlinear mixed-effects analysis of the relationship be-
tweenABT-126 estimated plasma exposure (model estimated
area under the plasma concentration time curve over a dosing
interval at steady-state; AUC) and change from baseline in
the ADAS-Cog scores was conducted using the software
NONMEM (version 7.1; Icon, Ellicott City, MD, USA).
The analysis accounted for the time course of placebo effect,
ABT-126 effect relative to its exposure, inter-subject vari-
ability in placebo and ABT-126 effects, and residual random
error. In this analysis, the Liklihood Ratio Test was used for
comparing rival hierarchical models where a decrease in
NONMEM objective function value (22 log likelihood) of
3.84 points was necessary to consider the improvement in
model performance statistically significant at a 5 0.05 and
1 degree of freedom. The Akaike information criterion was
used for comparing rival nonhierarchical models.
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3.1. Subjects
A total of 274 subjects were randomized from Bulgaria
(n 5 66), South Africa (n 5 51), the United Kingdom
(n 5 52), the Czech Republic (n 5 40), Slovakia (n 5 38),
and the United States (n 5 27), with 93.8% (n 5 257)
completing the trial. Disposition is presented in Fig. 1. De-
mographic characteristics were generally well balanced
among treatment groups with the exception of gender
(Table 1). Approximately 40% of subjects had previously
received pharmacotherapy for AD with the majorityAssessed
(n
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Fig. 1. Subject d(28.8%) taking supplements, nootropic agents, or vitamins
(e.g., Ginkgo biloba, piracetam, latrepirdine, tiapride,
vitamin E). Fewer subjects had previously taken AChEIs
(donepezil [8.8%], rivastigmine [4.7%], and galantamine
[2.6%]; Table 1).3.2. Efficacy
Nine subjects (3.3%) were not included in the primary
efficacy analysis due to missing baseline and/or on-
treatment 11-item ADAS-Cog total scores (Fig. 1). All
interim efficacy evaluations were conducted but led to no for eligibility
=358)
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• Withdrew consent: n=9
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Table 1
Baseline demographic characteristics
Characteristics Placebo ABT-126, 5 mg ABT-126, 25 mg Donepezil, 10 mg All subjects
Number of subjects 68 68 70 68 274
Age, y, mean 6 SD 73.6 6 8.23 74.0 6 7.47 75.7 6 7.35 72.4 6 8.42 73.9 6 7.92
Age ,75 y, n (%) 34 (50.0) 33 (48.5) 30 (42.9) 41 (60.3) 138 (50.4)
Age 75 y, n (%) 34 (50.0) 35 (51.5) 40 (57.1) 27 (39.7) 136 (49.6)
Female, n (%)* 42 (61.8) 47 (69.1) 48 (68.6) 31 (45.6) 168 (61.3)
Male, n (%) 26 (38.2) 21 (30.9) 22 (31.4) 37 (54.4) 106 (38.7)
White, n (%) 64 (94.1) 66 (97.1) 68 (97.1) 65 (95.6) 263 (96.0)
BMI, kg/m2, mean 6 SD 25.3 6 4.63 26.3 6 4.40 25.7 6 4.05 25.7 6 3.72 25.8 6 4.20
APOE ε4 positive 38 (55.9) 37 (56.1) 26 (38.8) 35 (53.0) 136 (50.9)
Age at AD symptom onset, y, mean 6 SD 70.1 6 8.62 70.6 6 7.65 72.0 6 7.69 69.3 6 8.72 70.5 6 8.20
Years since AD symptom onset*, mean6 SD 3.5 6 2.27 3.4 6 2.24 3.7 6 2.45 3.1 6 2.01 3.4 6 2.25
Age at AD diagnosis, y, mean 6 SD 72.3 6 8.47 72.5 6 7.50 74.2 6 7.41 71.2 6 8.71 72.6 6 8.07
Years since AD diagnosis, mean 6 SD 1.3 6 1.62 1.5 6 1.71 1.5 6 1.52 1.1 6 1.28 1.3 6 1.54
Family history of AD, n (%) 15 (22.1) 12 (17.6) 17 (24.3) 11 (16.2) 55 (20.1)
Medication used for treatment of ADy, n (%) 25 (36.8) 31 (45.6) 28 (40.0) 23 (33.8) 107 (39.1)
Donepezil 4 (5.9) 7 (10.3) 10 (14.3) 3 (4.4) 24 (8.8)
Galantamine 3 (4.4) 1 (1.5) 3 (4.3) 0 7 (2.6)
Memantine 0 3 (4.4) 5 (7.1) 1 (1.5) 9 (3.3)
Rivastigmine 4 (5.9) 3 (4.4) 3 (4.3) 3 (4.4) 13 (4.7)
Otherz 17 (25.0) 27 (39.7) 17 (24.3) 18 (26.5) 79 (28.8)
ADAS-Cog (11-item), mean 6 SDx 24.7 6 11.65 25.6 6 10.30 28.8 6 10.84 25.1 6 10.95 26.1 6 11.01
MMSE score, mean 6 SD 19.7 6 3.95 18.7 6 3.62 18.3 6 3.72 19.6 6 3.82 19.1 6 3.81
Abbreviations: SD, standard deviation; BMI, body mass index; AD, Alzheimer’s dementia; APOE, apolipoprotein E; ADAS-Cog, Alzheimer’s Disease
Assessment Scale-cognitive subscale; MMSE, Mini-Mental Status Examination.
NOTE. *P 5 .017 (Fisher’s exact test).
*Time from onset of AD symptoms or diagnosis to first dose of study drug.
ySubjects were not allowed to take donepezil (unless randomized to that treatment) galantamine, memantine, or rivastigmine after enrolling in the study.
zOther prestudy medications or supplements used by 5 subjects included Ginkgo biloba, piracetam, latrepirdine, tiapride, and vitamin E.
xBaseline results based on a total of 271 subjects.
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the 11-item ADAS-Cog are presented in Fig. 2. In the pri-
mary efficacy analysis, a trend of greater LS mean changes
from baseline (improvement) to the final evaluation in the
11-item ADAS-Cog total score was observed for ABT-126
25 mg (P 5 .095) and donepezil (P 5 .057) compared
with placebo; ABT-126 5 mg was similar to placebo. In
the MMRM analysis of the 11-item ADAS-Cog total score,
the LS mean difference between ABT-126 25 mg and pla-
cebo increased over time:20.84 at week 4 (90% confidence
interval [CI] 21.92 to 0.23, P 5 .098), 21.11 at week 8
(90% CI 22.47 to 0.26, P 5 .091), and 21.14 at week 12
(90% CI 22.65 to 0.37, P 5 .107). Similarly, the LS mean
difference between donepezil and placebo increased over
time, reaching statistical significance at week 12: 20.68 at
week 4 (90% CI 21.75 to 0.40, P 5 .149), 20.70 at week
8 (90% CI 22.06 to 0.66, P 5 .199), and 21.57 at week
12 (90% CI 23.08 to 20.07, P 5 .043). No differences
were observed in the ABT-126 5 mg treatment group LS
mean change compared with placebo over the 12 weeks.
No treatment-by-subgroup interactions were observed for
gender, age, country, or APOE ε4 allele status on the
ADAS-Cog 11-item total score.
ANCOVA results for secondary efficacy measures are
presented in Table 2. Both ABT-126 25 mg- and
donepezil-treated subjects had significant improvements inthe 13-item ADAS-Cog total score in the ANCOVA anal-
ysis. In the MMRM analysis of the 13-item ADAS-Cog total
score, the ABT-126 25 mg treatment group LS mean differ-
ence from placebo was 22.13 at week 4 (90% CI 23.36 to
20.89, P 5 .002), 22.06 at week 8 (90% CI 23.69 to
20.44, P 5 .018), and 21.61 at week 12 (90% CI 23.38
to 0.17, P 5 .068). The donepezil treatment group LS
mean difference from placebo was 21.53 at week 4 (90%
CI 22.75 to 20.31, P 5 .020), 21.85 at week 8 (90% CI
23.46 to 20.24, P 5 .030), and 22.48 at week 12 (90%
CI 24.23 to 20.72, P 5 .010).
No statistically significant differences in CIBIC-plus
scores were observed in the ANCOVA or MMRM analyses
between either ABT-126 dose group and placebo. The done-
pezil treatment group had a trend in the percentage of sub-
jects with any improvement (46.2%) compared with
placebo (33.3%, P5 .093) in the final CIBIC-plus rating; re-
sults for ABT-126 5 mg (36.8%) and ABT-126 25 mg
(39.1%) were not statistically significant.
Subgroup analyses of the 11-item ADAS-Cog total score
on the intent-to-treat data set indicated a statistically signif-
icant treatment-by-baseline MMSE category interaction
based on a difference in the treatment response for donepezil
between mild-and-moderate AD subjects (P 5 .097). Sub-
jects treated with ABT-126 25 mg had similar LS mean dif-
ferences from placebo of 21.9 (P 5 .066) and 21.3
Fig. 2. Least squares mean change from baseline over time in 11-item ADAS-Cog total score. The maximum likelihood, mixed-effect repeated-measures anal-
ysis of change from baseline to each study visit, and the primary analysis of covariance of change from baseline to the final evaluation for the ADASCog 11-item
total score. The standard error of the least squares means are denoted by error bars. Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale-
cognitive subscale; SD, standard deviation; LS, least squares; SE, standard error; CI, confidence interval.
L.M. Gault et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 81-9086(P 5 .178) in subgroups with baseline MMSE values 19
and 20, respectively, whereas donepezil subjects had LS
mean differences from placebo of 23.8 (P 5 .003) and 0.5
(P 5 .661) in subgroups with baseline MMSE values 19
and 20, respectively.3.3. Pharmacokinetics and the ADAS-Cog scores
exposure-response analysis
The observed ABT-126 plasma concentrations were
generally consistent with the expected exposures for the
evaluated dose levels, indicating good adherence to study
medication.
The exposure-response nonlinear mixed-effects analysis
indicated a statistically significant relationship between
ABT-126 exposure (plasma AUC over a dosing interval esti-
mated based on the sparse pharmacokinetic samples) and the
change from baseline in both the ADAS-Cog 11- and
13-item total scores (P , .05). The slope of the exposure-
response relationship from the nonlinear mixed-effects anal-
ysis was in agreement with the slope from a simple linear
regression of the data. A pictorial representation of theexposure-response relationship for the ADAS-Cog 11 scores
is depicted in Fig. 3.
The analysis suggested that higher exposure of ABT-126
might be associated with higher efficacy because a plateau of
the relationship between ABT-126 AUC and the change
from baseline in the ADAS-cog scores could not be dis-
cerned based on available data.3.4. Safety
The mean duration of treatment in this 12-week (84 day)
trial was 81.5 days (SD5 13.09), with no statistically signif-
icant differences observed across treatment groups. Overall,
study drug adherence was approximately 96% as determined
by the investigators and was similar across the treatment
groups.
Treatment-emergent AEs and serious adverse events
(SAEs) are summarized in Table 3. When comparing sub-
jects treated with ABT-126 versus placebo, no statistically
significant differences were observed in the incidence of
AEs or those considered possibly or probably related to
study drug. The most frequently reported AEs in ABT-
Table 2
Analysis of covariance of change from baseline to the final evaluation in secondary efficacy variables
Variables n
Observed mean total score 6 SD
LS mean of
change 6 SE
Difference from placebo
Baseline Final LS mean 6 SE 90% CI
P value
(one-sided)
ADAS-Cog 13-item total score (Y in score indicates improvement)
Placebo 65 35.53 6 12.19 34.28 6 14.24 20.78 6 0.74
ABT-126 5 mg 66 37.04 6 11.32 35.92 6 12.07 20.90 6 0.73 20.13 6 1.03 21.83 to 1.58 .451
ABT-126 25 mg 64 40.85 6 11.99 38.08 6 13.81 22.60 6 0.75 21.83 6 1.05 23.57 to 20.09 .042*
Donepezil 64 37.44 6 12.37 33.90 6 13.37 23.27 6 0.74 22.49 6 1.04 24.21 to 20.78 .009*
MMSE ([ in score indicates improvement)
Placebo 67 19.72 6 3.98 20.43 6 4.99 0.47 6 0.33
ABT-126 5 mg 68 18.74 6 3.62 19.65 6 4.98 0.81 6 0.32 0.34 6 0.46 20.41 to 1.09 .229
ABT-126 25 mg 69 18.30 6 3.75 19.25 6 4.92 0.88 6 0.32 0.41 6 0.46 20.34 to 1.17 .183
Donepezil 66 19.50 6 3.80 20.73 6 4.86 1.00 6 0.33 0.53 6 0.46 20.22 to 1.29 .122
CIBIS and CIBIC-Plusy
Placebo 66 3.91 6 0.89 3.80 6 0.85 3.83 6 0.10
ABT-126 5 mg 68 3.85 6 0.82 3.75 6 0.89 3.76 6 0.10 20.07 6 0.14 20.31 to 0.16 .306
ABT-126 25 mg 69 4.01 6 0.81 3.83 6 0.84 3.81 6 010 20.02 6 0.14 20.25 to 0.21 .443
Donepezil 65 3.82 6 0.83 3.62 6 0.84 3.67 6 0.10 20.16 6 0.14 20.40 to 0.07 .128
NPI, 12-item total score (Y in score indicates improvement)
Placebo 67 8.67 6 9.78 6.13 6 7.94 23.00 6 1.04
ABT-126 5 mg 68 8.38 6 10.82 8.31 6 15.62 20.57 6 1.03 2.43 6 1.45 0.04 to 4.82 .953
ABT-126 25 mg 69 13.29 6 13.40 10.52 6 11.59 22.38 6 1.03 0.62 6 1.46 21.79 to 3.03 .664
Donepezil 66 10.97 6 13.19 9.29 6 14.50 21.92 6 1.04 1.07 6 1.46 21.34 to 3.49 .768
ADCS-ADL total score ([ in score indicates improvement)
Placebo 67 53.01 6 16.18 54.45 6 17.31 1.58 6 0.86
ABT-126 5 mg 68 52.71 6 16.05 53.09 6 16.89 0.42 6 0.85 21.16 6 1.19 23.12 to 0.81 .834
ABT-126 25 mg 68 47.09 6 16.89 47.68 6 19.25 0.44 6 0.85 21.14 6 1.21 23.14 to 0.86 .827
Donepezil 66 49.76 6 16.93 52.71 6 16.87 2.95 6 0.86 1.37 6 1.21 20.62 to 3.36 .128
QoL-AD, Subject total score ([ in score indicates improvement)
Placebo 63 34.65 6 5.48 36.06 6 6.14 1.19 6 0.53
ABT-126 5 mg 67 35.58 6 5.22 35.55 6 5.19 0.12 6 0.51 21.07, 0.72 22.26 to 0.13 .929
ABT-126 25 mg 66 35.45 6 4.88 35.09 6 5.46 20.18 6 0.51 21.37, 0.73 22.58 to 20.17 .970
Donepezil 63 34.35 6 5.19 34.92 6 5.41 0.24 6 0.52 20.95, 0.73 22.16 to 0.26 .902
QoL-AD, caregiver total score ([ in score indicates improvement)
Placebo 66 34.67 6 5.66 34.73 6 5.40 0.44 6 0.47
ABT-126 5 mg 67 33.37 6 5.84 33.87 6 6.20 0.49 6 0.46 0.06 6 0.65 21.02 to 1.13 .466
ABT-126 25 mg 66 31.21 6 5.87 32.02 6 5.65 0.35 6 0.47 20.09 6 0.67 21.20 to 1.02 .552
Donepezil 63 32.35 6 6.15 32.59 6 6.06 0.02 6 0.48 20.42 6 0.67 21.53 to 0.69 .735
Abbreviations: SD, standard deviation; LS, least squares; SE, standard error; CI, confidence interval; ADAS-Cog, Alzheimer’s Disease Assessment Scale-
cognitive subscale; MMSE, Mini-Mental Status Examination; CIBIS, Clinician Interview-Based Impression of Severity; CIBIC, Clinician Interview-Based
Impression of Change; NPI, Neuropsychiatric Inventory; ADCS-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living; QoL-AD, Quality
of Life-Alzheimer’s Disease.
*Statistically significant versus placebo (one-sided P value from analysis of covariance).
yThe CIBIS was conducted at baseline and the CIBIC-Plus at the final visit. CIBIC-Plus ratings range from 1, markedly improved to 7, markedly worse. LS
means (SE) are presented instead of LS mean (SE) of change.
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tract infection (all 4.3%) compared with nausea (8.8%) and
diarrhea and vomiting (both 7.4%) in the donepezil group
(Table 3). Of the 112 subjects who experienced an AE, the
maximum severity in 103 (92.0%) was mild or moderate.
All SAEs were considered by the investigators as not related
or probably not related to the study drug.
No consistent, clinically significant changes in laboratory
or vital sign results were noted across treatment groups. Sta-
tistically significant differences between the ABT-126 25mg
group and placebowere observed in mean change from base-
line to final for the Bazett QTc (QTcB) interval (10.4 milli-
seconds, standard error [SE]5 4.7, P5 .026) and FridericiaQTc (QTcF) interval (9.5 milliseconds, SE5 4.4, P5 .032).
The significant differences from placebo emerged at week
12 and were related to increases in mean values in the
ABT-126 25 mg group, as well as to decreases in the placebo
group. Compared with placebo, no significant differences in
QTcB or QTcF were observed in any treatment group at
weeks 2, 4, and 8. A significant decrease in mean final heart
rate (25.3 bpm, SE5 1.8, P5 .004) was noted for donepezil
compared with placebo, consistent with data previously re-
ported for donepezil [27]. In addition, the donepezil treat-
ment group showed a significant increase in the QT
interval at the final visit (11.5 milliseconds, SE 5 5.5,
P 5 .037) but this was not accompanied by a significant
Fig. 3. Relationship between ABT-126 exposure and the change from base-
line in 11-item ADAS-Cog total score. Abbreviations: ADAS-Cog, Alz-
heimer’s Disease Assessment Scale-cognitive subscale; CI, confidence
interval; AUC, area under the plasma concentration time curve.
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potentially clinically significant changes in ECG parameters
was low in the ABT-126 25 mg and donepezil treatment
groups and similar to those observed across treatment
groups.
Exploratory analyses indicated a statistically signifi-
cantly higher LS mean PWC-20 score for the ABT-126Table 3
Summary of treatment-emergent adverse events
Overall, n (%) Placebo n 5 68
ABT-126
5 mg n 5
Any adverse event 26 (38.2) 29 (42.6)
Discontinued due to AE 2 (2.9) 1 (1.5)
Severe AE 3 (4.4) 0
Serious AE 3 (4.4) 2 (2.9)
Deathsy 1 (1.5) 0
Adverse events reported by 5.0% of subjects in any treatment group, MedDRA
Diarrhea 2 (2.9) 2 (2.9)
Nausea 1 (1.5) 4 (5.9)
Headache 1 (1.5) 1 (1.5)
Vomiting 1 (1.5) 1 (1.5)
Fall 1 (1.5) 2 (2.9)
Urinary tract infection 0 4 (5.9)
Serious adverse events occurring during the double-blind period, MedDRA prefe
Atrial fibrillation 1 (1.5) 0
Bradycardia 0 0
Cholecystitis acute 0 0
Completed suicide 1 (1.5) 0
Hyponatremia 0 1 (1.5)
Lower respiratory tract infection 0 0
Nausea 0 0
Sinus arrhythmia 1 (1.5) 0
Vomiting 0 0
Withdrawal syndrome 0 0
Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulato
*Nine subjects experienced serious AEs during the double-blind period and fou
yOne placebo-treated subject completed suicide and one subject who took ABT
ered related to study drug.25 mg group (3.32, SE 5 0.38) compared with placebo
(1.64, SE 5 0.38, P 5 .002). Although this suggested
greater severity in withdrawal symptoms from ABT-126
25 mg treatment, reported symptoms were generally of
mild intensity and there were no treatment-group differ-
ences in AEs spontaneously reported during the posttreat-
ment period.4. Discussion
The treatment effects in the donepezil group confirmed
that the study design was sufficient to detect a trend toward
improvement on the 11-item ADAS-Cog and significant
improvement on the 13-item ADAS-Cog. The ABT-126
25 mg treatment group exhibited a 1.19-point improvement
on the 11-item ADAS-Cog in this proof-of-concept study
(P5 .095), whereas the improvement in the donepezil group
was21.43 points (P5 .057). There appeared to be some ef-
fect of dose on the ABT-126 treatment response, as the 5 mg
dose group did not exhibit numerical improvement over pla-
cebo. Neither donepezil nor ABT-126 demonstrated
improvement on secondary efficacy measures, although
the sample size was intended to provide power only for the
primary outcome.
Overall, ABT-126 was generally well tolerated in sub-
jects with AD and exhibited an adequate safety profile to
support continued development at higher doses. Few68
ABT-126
25 mg n 5 70
Donepezil
10 mg n 5 68
All subjects
n 5 274
28 (40.0) 29 (42.6) 112 (40.9)
1 (1.4) 5 (7.4) 9 (3.3)
2 (2.9) 4 (5.9) 9 (3.3)
3 (4.3) 5 (7.4) 13 (4.7)*
1 (1.4) 0 2 (0.7)
preferred term
4 (5.7) 5 (7.4) 13 (4.7)
1 (1.4) 6 (8.8) 12 (4.4)
4 (5.7) 4 (5.9) 10 (3.6)
3 (4.3) 5 (7.4) 10 (3.6)
4 (5.7) 2 (2.9) 9 (3.3)
2 (2.9) 3 (4.4) 9 (3.3)
rred term
0 0 1 (0.4)
1 (1.4) 0 1 (0.4)
0 1 (1.5) 1 (0.4)
0 0 1 (0.4)
0 0 1 (0.4)
0 1 (1.5) 1 (0.4)
1 (1.4) 0 1 (0.4)
0 0 1 (0.4)
1 (1.4) 0 1 (0.4)
0 1 (1.5) 1 (0.4)
ry Activities.
r subjects during the follow-up period.
126 25 mg died 18 d post-dose of cardiac failure. Neither death was consid-
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and SAEs was low and comparable across dose groups, and
no SAEs were considered probably related or related to the
study drug. Consistent clinically meaningful changes in lab-
oratory or vital signs were not observed in ABT-126 treat-
ment groups.
The difference in change from baseline in the QTcB and
QTcF intervals between the ABT-126 25 mg group and pla-
cebo at week 12 is of undetermined clinical significance. It is
likely that this finding would have been observed shortly af-
ter steady-state levels were reached (i.e., before the week 2
visit) if the changes were related to ABT-126 treatment.
The emergence of QTc changes after several months of treat-
ment is not typical of drug-induced QTc changes and there-
fore not considered related to ABT-126 administration.
Other a7 nAChR agonists, including EVP-6124 [9] and
MEM3454/RG3487 [10], also showed evidence of procog-
nitive effects in subjects with mild-to-moderate AD. Phase
2 studies conducted with these agents also revealed no safety
signals of concern.
Doses in this trial were selected to provide plasma expo-
sures at or above those resulting in improved cognitive per-
formance in preclinical models. The exposure-response data
suggest higher doses may yield improved efficacy. Data
from this trial helped to guide dose selection and target pa-
tient population for subsequent clinical studies of ABT-
126 that explored a higher dose range. Two phase 2 studies
exploring a dose range of 25–75 mg in patients with mild-
to-moderate AD either as monotherapy or add-on therapy
to AChEIs were recently completed, and preliminary data
were disclosed [28,29]. Initial results suggest that even at
higher doses, the degree of efficacy exhibited by ABT-126
as monotherapy or add-on therapy is insufficient to support
further development.
The present study had several limitations, including an
uncharacteristically small donepezil response, short treat-
ment duration, and disproportionate subject enrollment
across the six participating countries. The donepezil
improvement of 21.43 points was less than what has usu-
ally been observed in 24-week studies of donepezil where
decreases were approximately 2.8 points (95% CI 23.74 to
22.10) [30], suggesting that the sensitivity of the trial to
detect treatment effects was limited. The trial design
included a relatively short 12-week treatment duration
and no wash out period; it was adequately designed to
detect the onset of treatment effect but did not provide use-
ful information about the durability of this effect. In addi-
tion, the proportion of subjects enrolled from each country
varied from approximately 0.1–0.25. Differences in appli-
cation of the criteria for subject selection or the acquisition
of the outcome measures may have created additional vari-
ability in the data that prevented detection of a treatment
effect for donepezil that was more consistent with previous
trial results.
Other a7 nAChR agonists, including encenicline (EVP-
6124) [9] and MEM3454/RG3487 [10], also showedevidence of procognitive effects in subjects with mild-to-
moderate AD, and phase 2 studies conducted with these
agents also revealed no safety signals of concern. Ongoing
randomized, placebo-controlled, phase 3 studies of enceni-
cline (NCT01969123 and NCT01969136) will assess the
safety and efficacy of high-dose and low-dose encenicline
in subjects with mild-to-moderate AD who are currently or
were previously taking stable doses of AChEIs. The results
from these studies will provide additional evidence about
the efficacy and safety of a7 nAChR agonists in the treat-
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1. Systematic review: Data regarding the preclinical
and clinical effects of a7 nicotinic acetylcholine re-
ceptor agonists were acquired via searches of online
databases such as PubMed and presentations from
scientific meetings. The information obtained is sum-
marized and cited.
2. Interpretation: In this double-blind, randomized,
placebo-controlled, proof-of-concept study, among
the first with a7 nicotinic acetylcholine receptor
agonists, no significant cognitive improvement was
observed in mild-to-moderate Alzheimer’s dementia
patients.
3. Future directions: Additional studies of ABT-126
and other a7 agonists as monotherapy or add-on
therapy in the treatment of patients with mild-to-
moderate Alzheimer’s dementia should be per-
formed.
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